David Spigel, MD, discusses the significant benefits of durvalumab as consolidation therapy following standard ...

An exploratory analysis shows a reduction in extrathoracic metastases and prolonged time to progression or death due to any ...

Matt Galsky, MD, discusses the phase 3 NIAGARA trial that led to the recent FDA approval of durvalumab in muscle-invasive ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

Approval was based on improved survival outcomes vs platinum-based chemotherapy as demonstrated in the phase 3 NIAGARA study.

The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer.

The FDA has approved neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab after radical cystectomy in MIBC.

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

Galsky, MD. The FDA recently approved perioperative durvalumab (Imfinzi) with neoadjuvant chemotherapy for adult patients with muscle-invasive bladder cancer (MIBC). The approval was supported by data ...

The FDA has approved durvalumab (Imfinzi; AstraZeneca) for muscle-invasive bladder cancer in combination with chemotherapy before surgery. The decision was based on the performance of the anti–PD-L1 ...